success
antimicrobi
stewardship
am
face
numer
barrier
transplant
immunocompromis
antimicrobi
use
respiratori
virus
common
pathogen
associ
commun
acquir
pneumonia
present
opportun
interest
stewardship
prolong
antibiot
therapi
set
viral
pneumonia
popul
associ
increas
length
stay
develop
resist
use
rapid
diagnost
particularli
respiratori
viru
panel
rvp
recommend
am
initi
reduc
inappropri
antibiot
therapi
effect
common
respiratori
respiratori
viru
polymeras
chain
reaction
pcr
test
laboratori
advantag
high
sensit
fast
turnaround
time
littl
hour
compon
make
attract
tool
am
comparison
standard
respiratori
howev
conflict
evid
benefici
impact
clinic
outcom
resourc
util
decreas
antibiot
durat
therapi
hospit
length
purpos
studi
evalu
impact
antimicrobi
util
follow
implement
rvp
coupl
am
audit
feedback
immunocompromis
patient
studi
intervent
immunocompromis
patient
test
rvp
observ
respiratori
viru
season
rv
rvp
test
util
octob
without
am
audit
follow
year
octob
rvp
detect
respiratori
pathogen
biofir
filmarray
salt
lake
citi
ut
usa
implement
concurr
weekday
am
call
provid
multidisciplinari
educ
use
rvp
present
distribut
prior
prospect
audit
feedback
rvp
result
pilot
round
pharmacist
am
servic
rvp
analyz
pm
daili
transplant
patient
patient
immunocompromis
condit
icu
respiratori
tract
infect
test
rvp
includ
pneumonia
diagnosi
discret
critic
care
transplant
team
per
document
progress
discharg
summari
immunocompromis
defin
solid
organ
transplant
sot
hematopoiet
stem
cell
transplant
hsct
anc
cellscc
count
cellscc
receiv
immunosuppressivecytotox
therapi
alkyl
agent
anthracyclin
mtor
calcineurin
inhibitor
thymoglobulin
inhibitor
agonist
corticosteroid
equival
least
week
prednison
mg
daili
patient
year
age
pregnant
death
discharg
prior
result
rvp
exclud
time
specimen
collect
final
result
electron
medic
record
defin
turnaround
time
studi
power
effect
size
turnaround
time
alpha
power
yield
sampl
size
outcom
interest
empir
antimicrobi
durat
therapi
hospit
length
stay
time
intervent
intervent
consist
antimicrobi
optim
via
antibiot
initiationdiscontinu
antivir
modif
immunosuppress
regimen
begin
collect
specimen
hour
follow
rvp
result
empir
durat
therapi
defin
antibiot
therapi
pneumonia
prior
rvp
result
andor
target
therapi
intervent
use
categor
variabl
use
continu
variabl
factor
associ
antimicrobi
optim
examin
bivari
analysi
spss
version
use
statist
analys
one
hundr
immunocompromis
patient
test
rvp
analyz
n
n
median
age
year
total
popul
femal
differ
baselin
characterist
test
test
except
posit
rvp
chronic
obstruct
pulmonari
diseaseasthma
congest
heart
failur
tabl
among
patient
immunocompromis
factor
renal
liver
lung
common
type
sot
metastat
cancer
immunosuppress
medic
relat
sot
hsct
cellscc
pneumonia
diagnos
patient
microbiolog
confirm
bacteri
pneumonia
via
respiratori
cultur
patient
bacteri
respiratori
pathogen
observ
common
staphylococcu
aureu
follow
streptococcu
pneumonia
streptococcu
speci
posit
rvp
preval
pathogen
isol
influenza
coronavirus
rhinovirusenteroviru
two
patient
confirm
coinfect
viral
bacteri
pneumonia
primari
outcom
turnaround
time
reduc
hour
p
reduc
hour
hour
p
rvp
significantli
impact
frequenc
antimicrobi
optim
intervent
vs
reduc
specimen
collect
hour
p
also
differ
group
type
intervent
discontinu
addit
length
stay
empir
antibiot
durat
therapi
intervent
discontinu
oseltamivir
follow
addit
antivir
agent
antibiot
discontinu
rvp
result
n
posit
rvp
n
subset
patient
posit
rvp
test
shorter
length
stay
vs
day
p
like
diagnosi
upper
respiratori
tract
infect
urti
vs
p
characterist
associ
prescrib
inertia
posit
bacteri
respiratori
cultur
renal
transplant
isol
respiratori
viru
mostli
driven
influenza
associ
antimicrobi
optim
tabl
rapid
diagnost
test
quickli
becom
influenti
aspect
stewardship
model
recommend
practic
guidelin
initi
am
analyz
immunocompromis
patient
test
rvp
am
implement
led
signific
reduct
turnaround
time
increas
diagnost
yield
compar
patient
rvp
test
broader
respiratori
panel
pcr
includ
coronavirus
human
metapneumoviru
compar
like
contribut
yield
howev
littl
indic
manag
patient
significantli
modifi
basi
improv
diagnost
certainti
rvp
differ
group
durat
therapi
length
stay
intervent
observ
increas
diagnost
certainti
may
result
faster
discharg
patient
posit
rvp
shorter
length
stay
neg
rvp
yet
infrequ
antibiot
group
compar
previou
suspect
coinfect
critic
statu
increas
oxygen
requir
specif
radiograph
find
pend
cultur
may
contribut
antibiot
continu
recent
prospect
multicent
surveil
studi
commun
acquir
pneumonia
major
pathogen
isol
nasopharyngealoropharyng
pcr
urinari
antigen
cultur
hospit
patient
pneumonia
respiratori
virus
low
incid
popul
exclud
immunocompromis
individu
studi
would
provid
import
context
current
pattern
pneumonia
transplant
patient
antimicrobi
decis
make
popul
confirm
coinfect
differ
icu
popul
surpris
bacteri
pneumonia
neg
predictor
antimicrobi
adjust
similar
associ
renal
transplant
patient
unexpect
find
appropri
antimicrobi
manag
may
streamlin
target
educ
effort
toward
healthcar
provid
leader
studi
limit
retrospect
natur
method
design
captur
appropri
rvp
util
potenti
opportun
may
exist
patient
test
well
select
timefram
hospit
patient
sot
diagnos
respiratori
tract
infect
rvp
test
studi
sampl
limit
heterogen
critic
ill
immunocompromis
andor
transplant
patient
test
rvp
reach
intend
initi
sampl
size
within
studi
time
frame
although
differ
turnaround
time
observ
given
minim
chang
prescrib
behavior
howev
unlik
larger
sampl
size
would
result
observ
differ
secondari
endpoint
season
present
anoth
challeng
intervent
driven
presenc
absenc
influenza
addit
discontinu
oseltamivir
pathogen
respiratori
syncyti
viru
adenoviru
rare
isol
result
also
suggest
institut
avail
molecular
influenza
test
util
prior
rvp
major
cost
differ
similar
turnaround
time
bacteri
pneumonia
confirm
inpati
diagnosi
round
team
cultur
growth
pathogen
lower
respiratori
sampl
rvp
present
studi
use
nasopharyng
sampl
detect
virus
addit
pneumonia
c
pneumonia
b
pertussi
high
qualiti
lower
respiratori
sampl
pcr
test
may
provid
greater
confid
presenc
absenc
pathogen
pneumonia
technolog
yet
wide
avail
practic
patient
institut
rvp
gain
popular
practic
judici
use
patient
popul
interpret
respect
result
taken
higher
consider
optim
antimicrobi
manag
cost
care
improv
diagnost
yield
turnaround
time
may
surrog
ancillari
test
laboratori
labor
may
still
justifi
rvp
use
rvp
consist
use
tool
rather
addit
academ
inform
investig
am
resourc
util
warrant
critic
ill
immunocompromis
transplant
patient
none
